Penumbra to Spotlight Thrombectomy Leadership at J.P. Morgan Conference

ALAMEDA, CA – December 30, 2025 – Penumbra, Inc. is preparing to take the stage at the 44th Annual J.P. Morgan Healthcare Conference, an event that serves as a critical barometer for the entire medical industry. The company, a global leader in blood clot removal technology, announced its management will present on January 12, 2026, offering investors and industry peers a detailed look into its strategy, financial health, and technological pipeline.

For a company that has consistently outpaced market expectations, the presentation is more than a routine update. It is a key opportunity to reinforce its market dominance in thrombectomy and outline its vision for future growth amidst a rapidly evolving MedTech landscape.

A Bellwether Event for Healthcare Investment

The J.P. Morgan Healthcare Conference, held annually in San Francisco, is the industry's premier investment symposium. It's a high-stakes environment where multi-billion dollar deals are often initiated and where the trajectories of companies, both large and small, can be significantly influenced. For investors, the conference provides a concentrated dose of data, strategy, and executive insight that sets the tone for the year ahead.

Heading into 2026, the conference is expected to be dominated by several key themes. The integration of artificial intelligence into diagnostics and treatment, a potential surge in mergers and acquisitions driven by major patent expirations, and the explosive growth of the obesity drug market are all anticipated to be major topics of discussion. For medical device companies like Penumbra, the focus will be on demonstrating clear paths to profitability, showcasing disruptive innovation, and proving clinical superiority.

"This conference is where the narrative for the year is set," noted one industry analyst. "Investors are looking for companies that not only have a compelling story but also the data and financial discipline to back it up. A strong presentation here can have a lasting impact on valuation and strategic partnerships."

Financial Momentum and Investor Expectations

Penumbra arrives at the conference on the back of a remarkably strong financial year. Throughout 2025, the company consistently delivered results that surpassed analyst consensus, culminating in a standout third quarter. The company reported Q3 revenues of $354.7 million, a nearly 18% year-over-year increase, prompting management to raise its full-year revenue guidance to a range of $1.375 billion to $1.38 billion.

This growth has been fueled by the exceptional performance of its U.S. thrombectomy business, which saw an 18.5% increase in the third quarter. The venous thromboembolism (VTE) segment was a particular bright spot, with U.S. revenue soaring by an impressive 34%. This demonstrates robust adoption of Penumbra's technologies for treating conditions like pulmonary embolism (PE) and deep vein thrombosis (DVT).

Beyond top-line growth, the company has also demonstrated strong operational efficiency. Its gross margin expanded to 67.8% in the third quarter, a testament to a favorable product mix weighted towards its higher-margin thrombectomy devices and manufacturing productivity gains. Ending the quarter with over $470 million in cash and no debt, Penumbra presents a picture of financial stability and strength. This solid financial footing, combined with a strategic decision in 2024 to exit its non-core Immersive Healthcare business, signals a disciplined focus on its most profitable and impactful market segments. Investors will be keenly listening for how the company plans to leverage this financial strength to fund further innovation and market expansion in 2026.

Redefining Clot Removal with Advanced Technology

At the heart of Penumbra's success is its technological leadership, particularly its proprietary Computer Assisted Vacuum Thrombectomy (CAVT) platform. Unlike conventional methods, CAVT systems like the company's Lightning Intelligent Aspiration technology use advanced algorithms to differentiate between blood clots and flowing blood, allowing for the powerful and precise removal of life-threatening thrombi with a reduced risk of complications.

This technological edge was recently validated by the landmark STORM-PE clinical trial. The study demonstrated that using Penumbra's CAVT technology for intermediate-high-risk pulmonary embolism patients resulted in significantly improved functional outcomes and reduced strain on the heart compared to using anticoagulation drugs alone, all while maintaining a comparable safety profile. These results, published in the prestigious journal Circulation, provide powerful clinical evidence supporting the company's approach and are expected to be a cornerstone of its presentation.

Penumbra's innovation engine has also been highly active. In the past year, the company secured FDA clearance for its next-generation Lightning Bolt 16 and Lightning Flash 3.0 systems, which feature enhanced algorithms and hardware. Furthermore, it is making progress on its Thunderbolt device, designed to further enhance procedural safety. The company also broadened its portfolio with the launch of the ACCESS25 microcatheter for neurovascular procedures and the Ruby® XL and SwiftSET coil systems for vascular embolization. This continuous stream of new and improved products showcases a deep R&D pipeline that addresses a wide spectrum of vascular conditions from head-to-toe, reinforcing its claim as a comprehensive leader in the field.

Navigating a Competitive and Evolving Market

While Penumbra has established a formidable position, it operates in a highly competitive market. It vies with medical device giants like Medtronic and Stryker in the neurovascular stroke space and faces a specialized, formidable competitor in Inari Medical within the VTE market. To maintain its leadership, Penumbra relies on its key differentiators: the demonstrated efficacy of its CAVT technology, a broad portfolio covering both neurovascular and peripheral interventions, and a growing body of compelling clinical data.

Penumbra's presentation at the J.P. Morgan conference comes at a time of heightened investor interest in the MedTech sector. With an anticipated uptick in M&A activity, companies with innovative, clinically-proven technologies and strong financial performance are prime targets for both investment and acquisition. Penumbra's focus on minimally invasive technology for treating widespread and critical conditions like stroke and pulmonary embolism aligns perfectly with current investment trends that favor solutions offering clear patient benefits and healthcare system efficiencies.

As the company's management team prepares to detail its achievements and future plans, they will be speaking to an audience eager to identify the next wave of growth drivers in healthcare. The combination of market leadership, proven financial execution, and a pipeline of life-saving innovations positions Penumbra as a significant company to watch as the healthcare industry gathers in San Francisco.